Supriya Lifescience Ltd.
Snapshot View

View in App

Prices View details >>

202.75 -3.45 ▼-1.7%

02 February 2023, 04:01:00 PM
Volume: 29,169

Overview View Details >>

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.supriyalifescience.com
Market Cap 1,614.48 Cr.
Enterprise Value(EV) 1,455.35 Cr. 2022-09
Financial Indicators
Earnings per share (EPS) 15.90 Trailing Twelve Months Ending 2022-09
Price-Earning Ratio (PE) 12.62 Trailing Twelve Months Ending 2022-09
Industry PE 32.44 Trailing Twelve Months Ending 2022-09
Book Value / Share 81.00 Trailing Twelve Months Ending 2022-09
Price to Book Value 2.48 Calculated using Price: 200.60
Dividend Yield 0.30 Period Ending 2022-03
No. of Shares Subscribed 8.05 Cr. 80,482,800 Shares
FaceValue 2
Company Profile
The company is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients (APIs), with a focus on research and development. The company has niche product offerings of various APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and antiallergic.

Delivery View Details >>

Delivered Qty
Traded Qty

Performance View Details >>

1 Day
-1.67%
1 Week
-6.59%
1 Month
-15.61%
3 Month
-29.36%
6 Month
-46.23%
1 Year
-57.97%
2 Year
5 Year
10 Year

Ratios View Details >>

9 years 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03
Return on Equity (%) 29.57 29.61 17.20 15.05 18.38 53.11 60.42 59.17 34.34
Return on Capital Employed (%) 19.43 15.83 12.27 11.48 13.80 36.52 49.67 60.12 43.34
Return on Assets (%) 5.42 5.37 2.80 2.40 3.59 15.82 24.90 31.61 25.73

Balance Sheet View Details >>

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2022-09* Rs. Cr.
Shh. Funds 30 37 42 46 55 94 149 269 616 652
Non Curr. Liab. 17 23 39 51 45 24 32 31 19 21
Curr. Liab. 83 115 150 144 146 135 155 146 100 89
Minority Int.
Equity & Liab. 130 176 231 241 245 253 336 445 735 762
Non Curr. Assets 52 73 102 126 126 120 138 180 237 268
Curr. Assets 78 103 129 115 120 133 198 265 498 494
Misc. Exp. not W/O
Total Assets 130 176 231 241 245 253 336 445 735 762

Profit Loss View Details >>

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2022-09 Rs. Cr. TTM
Net Sales 113 138 171 184 213 278 312 391 530 512
Other Income 2 2 2 7 9 8 11 5 8 14
Total Income 115 140 173 191 222 286 323 396 538 526
Total Expenditure -98 -121 -151 -166 -191 -213 -213 -218 -316 -315
PBIDT 16 20 22 25 31 73 109 178 222 211
Interest -6 -7 -10 -12 -11 -10 -7 -4 -4 -27
Depreciation -2 -2 -4 -5 -5 -5 -6 -7 -10 -11
Taxation -2 -2 -2 -2 -6 -18 -23 -44 -55 -45
Exceptional Items
PAT 6 8 6 6 9 39 73 124 152 128
Adjusted EPS 13 17 4 4 6 27 50 17 19 16

Cash Flow View Details >>

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr.
Cash Fr. Operatn. -6 14 27 28 49 116 76 49
Cash Fr. Inv. -23 -33 -27 -5 5 -25 -47 -60
Cash Fr. Finan. 30 21 -2 -20 -50 -29 -15 150
Net Change 1 2 -2 3 4 62 15 139
Cash & Cash Eqvt 5 7 6 9 12 75 89 228

Shareholding Pattern View Details >>

5 Qtrs 2021-12 (%) 2022-03 (%) 2022-06 (%) 2022-09 (%) 2022-12 (%)
Promoter 68.24 68.24 68.24 68.24 68.24
Public 31.76 31.76 31.76 31.76 31.76
Depository Receipts 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00

Announcements View Details >>

Mon, 23 Jan 2023
Appointment Of Chief Financial Officer & Key Managerial Personnel
Appointment of Mr. Krishna Raghunathan as the Chief Financial Officer (KMP) of the Company with effect from January 23 2023. Mr. Krishna Raghunathan is a dynamic professional with 23+ years of rich experience in financial management. In his last role Mr. Raghunathan worked for ~5 years as Vice President - Finance Treasury and Investor Relations with a listed pharmaceuticals Company. Mr. Raghunathan has a demonstrated history of working in diverse industries including pharmaceuticals packaging and information technology. Mr. Raghunathan is a seasoned pharma specialist with more than 2 decades of experience in companies like Dr. Reddys Laboratories Limited and Granules India Limited. His appointment is in line with companys strategy to achieve accelerated growth in the years to come.
Mon, 23 Jan 2023
Announcement under Regulation 30 (LODR)-Resignation of Director
Pursuant to regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 it is hereby informed that Mr. Balasaheb Sawant Whole Time Director and Key Managerial Personnel of the Company has tendered his resignation with effect from January 23 2023 due to the personal reason.
Mon, 23 Jan 2023
Announcement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO)
With reference to the captioned subject and pursuant to regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to inform you that the Board of Directors has approved the following change(s) in Key Managerial Personnel (Chief Financial Officer) of the Company at their meeting held today i.e. January 23 2023.Mr. Ashish Nayak has resigned from the position of Chief Financial Officer & KMP of the Company and the Board has accepted his resignation with effect from close of business hours on January 23 2023 however he will be relieved from the company on January 31 2023 for smooth transition to his successor.

Technical Scans View Details >>

Thu, 02 Feb 2023
Higher Delivery Quantity Higher Delivery Quantity
Higher Trade Quantity Higher Trade Quantity
Higher Trade and Delivery Quantity Higher Trade and Delivery Quantity
Close Crossing 52 Week Low Close Crossing 52 Week Low
Closing Below Previous Low Closing Below Previous Low

Related Stocks View Details >>

  • SALES
Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 241,852.96 1,008.00 -0.6%
Divi's Laboratories Ltd. 86,732.57 3,271.90 -2.5%
Cipla Ltd. 82,728.22 1,024.95 -0.7%
Dr. Reddy's Laboratories Ltd. 72,771.66 4,366.00 +0.4%
Apollo Hospitals Enterprise Ltd. 60,864.05 4,234.95 -0.8%
Torrent Pharmaceuticals Ltd. 52,144.29 1,541.15 +0.5%
Zydus Lifesciences Ltd. 43,787.95 432.60 -0.7%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-12 57.42 1,008.00 -0.6%
Divi's Laboratories Ltd. Consolidated 2022-09 29.03 3,271.90 -2.5%
Cipla Ltd. Consolidated 2022-12 31.36 1,024.95 -0.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-12 19.95 4,366.00 +0.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-09 72.52 4,234.95 -0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-12 62.77 1,541.15 +0.5%
Zydus Lifesciences Ltd. Consolidated 2022-09 22.59 432.60 -0.7%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-12 4.37 1,008.00 -0.6%
Divi's Laboratories Ltd. Consolidated 2022-09 7.16 3,271.90 -2.5%
Cipla Ltd. Consolidated 2022-12 3.65 1,024.95 -0.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-12 3.30 4,366.00 +0.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-09 10.17 4,234.95 -0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-12 8.18 1,541.15 +0.5%
Zydus Lifesciences Ltd. Consolidated 2022-09 2.63 432.60 -0.7%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 0.03 1,008.00 -0.6%
Divi's Laboratories Ltd. Consolidated 2022-03 0.00 3,271.90 -2.5%
Cipla Ltd. Consolidated 2022-03 0.04 1,024.95 -0.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 0.18 4,366.00 +0.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 0.47 4,234.95 -0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 0.68 1,541.15 +0.5%
Zydus Lifesciences Ltd. Consolidated 2022-03 0.25 432.60 -0.7%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 1,008.00 -0.6%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 3,271.90 -2.5%
Cipla Ltd. Consolidated 2022-03 13.10 1,024.95 -0.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.55 4,366.00 +0.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,234.95 -0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,541.15 +0.5%
Zydus Lifesciences Ltd. Consolidated 2022-03 15.51 432.60 -0.7%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 1,008.00 -0.6%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 3,271.90 -2.5%
Cipla Ltd. Consolidated 2022-03 13.10 1,024.95 -0.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.55 4,366.00 +0.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,234.95 -0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,541.15 +0.5%
Zydus Lifesciences Ltd. Consolidated 2022-03 15.51 432.60 -0.7%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 38,654.49 1,008.00 -0.6%
Divi's Laboratories Ltd. Consolidated 2022-03 8,959.83 3,271.90 -2.5%
Cipla Ltd. Consolidated 2022-03 21,763.34 1,024.95 -0.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 21,545.20 4,366.00 +0.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 14,662.60 4,234.95 -0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 8,508.04 1,541.15 +0.5%
Zydus Lifesciences Ltd. Consolidated 2022-03 15,265.20 432.60 -0.7%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 3,405.82 1,008.00 -0.6%
Divi's Laboratories Ltd. Consolidated 2022-03 2,960.45 3,271.90 -2.5%
Cipla Ltd. Consolidated 2022-03 2,559.47 1,024.95 -0.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 2,112.20 4,366.00 +0.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 1,101.10 4,234.95 -0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 777.18 1,541.15 +0.5%
Zydus Lifesciences Ltd. Consolidated 2022-03 2,326.40 432.60 -0.7%

FAQ's On Supriya Lifescience Ltd.

What is Supriya Lifescience share price?
Can I buy Supriya Lifescience shares now?
What is the Dividend Yield of Supriya Lifescience?
What is the Market Cap of Supriya Lifescience?
What are the key metrics to analyse Supriya Lifescience?
What is the 52 Week High and Low of Supriya Lifescience?
What is the trend of Supriya Lifescience share price?